Thursday, 29 November 2018

Reuters Health Report: China orders halt to gene-editing after outcry over babies

Reuters.com Newsletter

China orders halt to gene-editing after outcry over babies

The Chinese government on Thursday ordered a temporary halt to research activities for people involve in the editing human genes, after a Chinese scientist said he had edited the genes of twin babies.

Patents on pot? U.S. lawsuit puts cannabis claims to the test

In October, the U.S. government issued Axim Biotechnologies Inc a patent for a cannabis-based suppository to treat irritable bowel syndrome.

Alkermes schizophrenia treatment meets main goals in late-stage study

Alkermes Plc said on Thursday its treatment for schizophrenia met the main goals in a late-stage study and demonstrated a favorable weight profile, compared with antipsychotic agent olanzapine.

China mulls stockpiling pork to support farmers hit by swine fever

China may soon buy pork for its state reserves to support farmers struggling to sell their pigs amid an African swine fever epidemic that has ravaged the nation's hog herd, according to people who attended a government meeting this week.

Biocartis partners with AstraZeneca on lung cancer diagnostics

Belgian molecular diagnostics company Biocartis Group said on Thursday it had entered into an agreement with British drugmaker AstraZeneca to obtain faster lung cancer molecular diagnostic biomarker results in Europe.

Gunfire, threats and curfews slow Congo's fight against Ebola

When medics tried to reach Ebola patients in a village in eastern Democratic Republic of Congo during a recent surge in violence, they were blocked by men wielding machetes and axes.

Former Insys executive pleads guilty to opioid bribe scheme

A former executive at Insys Therapeutics Inc pleaded guilty on Wednesday to participating in a scheme to bribe doctors to prescribe the company's powerful opioid medication and entered into a deal to cooperate with prosecutors.

FDA approves first biosimilar to Roche cancer drug Rituxan

Celltrion Inc's Truxima on Wednesday became the first biosimilar to Roche Holding AG's $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin's lymphoma.

U.S. FDA approves Catalyst Pharma's rare disease drug

The U.S. Food and Drug Administration approved on Wednesday Catalyst Pharmaceuticals Inc's drug to treat a rare autoimmune disease.

Merck raised prices five drugs including Keytruda in November

Merck & Co Inc said on Wednesday it raised U.S. prices on five of its drugs earlier in November by between 1.5 percent and 6 percent, including its top-selling cancer treatment Keytruda.

Global warming will increase heat-related death and disease - study

Climate change is making more people around the world vulnerable to heat exposure, putting them at greater risk of heart and kidney disease, heat stress, and other heat-related killers, scientists warned on Wednesday.

Related Videos

Introducing the all-new
Reuters News app

The new Reuters News app is here, redesigned from the ground up to fit your busy life.

Get it now on iOS